A Phase 2 interventional study of Enzalutamide in Castration-Resistant Prostate Cancer (CRPC), sponsored by Astellas Pharma Inc. Completed at 7 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-06.
Sponsored by Astellas Pharma Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 63rd largest by enrollment, is one of 4 that started in 2011, is one of 65 in phase 2, and was the 9th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 78 · Phase 3 18 · Phase 4 7
First in 2005; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 52 across the 125 interventional studies. Of the 81 that completed or were terminated, 49 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 125 have an industry lead sponsor. The 10 most frequent:
Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.
53 studies in Prostatic Neoplasms by Astellas Pharma Inc: 5 open now, 7 under way, 1 of them phase 3. Of 46 finished, 13 (28%) have results posted.
Among the 53 studies in Prostatic Neoplasms by Astellas Pharma Inc, this one is the 23rd largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2011, is one of 14 in phase 2, and was the 19th registered.
Astellas Pharma Inc’s Prostatic Neoplasms studies by the year they started, since 2001.
13 of the studies testing enzalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT05873192M.D. Anderson Cancer CenterPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | 2026-12-31 |
| NCT03344211University of Southern CaliforniaEnzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, from their registry updates:
Among Astellas Pharma Inc’s 53 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
A study to assess the safety of continued administration of MDV3100 in subjects with Prostate Cancer who have already undergone treatment with MDV3100 and showed benefit.
This was a multi-center extension study in participants with prostate cancer who have completed MDV3100 treatment study to assess the long-term safety of continued administration of MDV3100, when judged by the investigator to be in the best interest of the participant. For the study duration, all participants with castration-resistant prostate cancer (CRPC) maintained androgen deprivation with a Luteinizing Hormone Releasing Hormone (LHRH) agonist/antagonist unless they underwent bilateral orchiectomy. Participants were discontinued from study drug when the continued administration of study drug was deemed to be not in the participants' best interest by the investigator based on clinical assessment. Throughout the study, safety and tolerability were assessed by the recording of adverse events, monitoring of vital signs and physical examinations, safety laboratory evaluations, and 12-lead electrocardiograms (ECGs). Participants had a safety follow-up visit 30 days after their last dose of study drug. Participants that did not meet any of the discontinuation criteria were eligible to continue to receive treatment with enzalutamide in study 9785-CL-0123 [NCT02960022] upon approval and activation of the study at the participating institution. Participants who enrolled in study 9785-CL-0123 [NCT02960022] were not required to have a safety follow-up visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male subjects and their female spouses/partners who are of must be using highly effective contraception1 consisting of two forms of (one of which must be a barrier method) starting at Screening and continue throughout the study period and for 3 months after final study drug administration. Male subjects must not donate sperm starting at Screening and throughout the study period and for at least 3 months after final study drug administration. 1Highly effective contraception is defined as:
Exclusion Criteria:
Subject will be excluded from participation if any of the following apply:
Use of the following prohibited medication/therapies:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 160 mg enzalutamide orally once a day. Participants continued on treatment unless the dose was reduced or treatment was interrupted during the study.
Drug: Enzalutamide
Oral
Also known as: MDV3100, ASP9785, Xtandi
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant administered study drug or who underwent study procedures and did not necessarily have a causal relationship with treatment. An abnormality identified during a medical test was defined as an AE only if the abnormality induced clinical signs or symptoms, required active intervention, required interruption, or discontinuation of study medication, or was clinically significant in the opinion of the investigator. An AE was defined as serious if it resulted in any of the following outcomes: Death, Was life-threatening, Persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, Congenital anomaly, or birth defect, Inpatient hospitalization or prolongation of hospitalization, Other medically important event. Drug-related AEs were those assessed by the investigator as AEs whose relationship to the to the study drugs could not be ruled out.
Time frame: From the date of the first dose of study drug to 30 days after last dose of study drug; the median duration of treatment was 392 days, and the maximum was 1926 days
The study was conducted at 1 site in the Republic of Moldova, 2 sites in South Africa and 4 sites in the United States. In order to participate, participants had to complete a prior study with enzalutamide, be in a state of at least stable disease and benefit from continued treatment with enzalutamide in the opinion of the investigator.
| Milestone | Enzalutamide |
|---|---|
| Started | 52 |
| Treatment received | 52 |
| Completed | 52 |
| Not completed | 0 |
An AE was defined as any untoward medical occurrence in a participant administered study drug or who underwent study procedures and did not necessarily have a causal relationship with treatment. An abnormality identified during a medical test was defined as an AE only if the abnormality induced clinical signs or symptoms, required active intervention, required interruption, or discontinuation of study medication, or was clinically significant in the opinion of the investigator. An AE was defined as serious if it resulted in any of the following outcomes: Death, Was life-threatening, Persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, Congenital anomaly, or birth defect, Inpatient hospitalization or prolongation of hospitalization, Other medically important event. Drug-related AEs were those assessed by the investigator as AEs whose relationship to the to the study drugs could not be ruled out.
| Participants | Enzalutamide |
|---|---|
| Any TEAE | 43 |
| Drug-Related TEAEs | 27 |
| Deaths | 5 |
| Serious TEAEs | 17 |
| Drug-Related Serious TEAEs | 5 |
| TEAEs Leading to Study Drug Discontinuation | 12 |
| Drug-Related TEAEs Lead to Study Discontinuation | 5 |
Collected over From the date of the first dose of study drug to 30 days after last dose of study drug; the median duration of treatment was 392 days, and the maximum was 1926 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enzalutimide | 2/52 (3.8%) | 17/52 (32.7%) | 33/52 (63.5%) |
| Event | Enzalutimide |
|---|---|
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 4/52 |
| AstheniaGeneral disorders | 2/52 |
| Spinal cord compressionNervous system disorders | 2/52 |
| Acute myocardial infarctionCardiac disorders | 1/52 |
| Atrial fibrillationCardiac disorders | 1/52 |
| TachycardiaCardiac disorders | 1/52 |
| Anal fissureGastrointestinal disorders | 1/52 |
| DiarrhoeaGastrointestinal disorders | 1/52 |
| Pancreatitis acuteGastrointestinal disorders | 1/52 |
| ProctalgiaGastrointestinal disorders | 1/52 |
| Event | Enzalutimide |
|---|---|
| FatigueGeneral disorders | 14/52 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 7/52 |
| Back painMusculoskeletal and connective tissue disorders | 7/52 |
| Decreased appetiteMetabolism and nutrition disorders | 6/52 |
| Hot flushVascular disorders | 6/52 |
| ConstipationGastrointestinal disorders | 5/52 |
| DiarrhoeaGastrointestinal disorders | 5/52 |
| HyponatraemiaMetabolism and nutrition disorders | 5/52 |
| AnaemiaBlood and lymphatic system disorders | 4/52 |
| NauseaGastrointestinal disorders | 4/52 |
The analysis population was the Safety Analysis Set (SAF), which consisted of participants who received at least one dose of enzalutamide during the extension study. This extension study's baseline was considered the original baseline from the prior parent studies with enzalutamide.
| Age, Continuous(years) | Enzalutamide |
|---|---|
| Geometric mean | 68.6 ± 7.39 |
| Sex: Female, Male(Participants) | Enzalutamide |
|---|---|
| Female | 0 |
| Male | 52 |
| Ethnicity (NIH/OMB)(Participants) | Enzalutamide |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 52 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Enzalutamide |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 2 |
| White | 47 |
| More than one race | 0 |
| Unknown or Not Reported | 3 |
| Duration of Prostate Cancer(months) | Enzalutamide |
|---|---|
| Geometric mean | 69.4 ± 64.10 |
| Primary Gleason Score at Initial Diagnosis(Participants) | Enzalutamide |
|---|---|
| Score 3 | 15 |
| Score 4 | 13 |
| Score 5 | 4 |
| Unknown | 20 |
| Secondary Gleason Score at Initial Diagnosis(Participants) | Enzalutamide |
|---|---|
| Score 3 | 9 |
| Score 4 | 14 |
| Score 5 | 9 |
| Unknown | 20 |
| Total Gleason Score at Initial Diagnosis(Participants) | Enzalutamide |
|---|---|
| Score 6 | 5 |
| Score 7 | 16 |
| Score 8 | 1 |
| Score 9 | 13 |
| Unknown | 17 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Ran from Oct 2011 to primary completion in Apr 2017, 65 months.
Results were first posted in Apr 2018, 1 year after primary completion.
Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 65 months is above that.
Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide